Clinical Trial

Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a multi-institutional Phase I/II study of an allogeneic KIR-HLA mismatched NK cell infusion (AdaptNK) and a short course of subcutaneous interleukin-2 (IL-2) administered after lymphodepleting chemotherapy \[cyclophosphamide (CY)/fludarabine (FLU)\] in patients with relapsed or refractory acute myelogenous leukemia (AML). AdaptNK is a natural killer (NK) cell product that is enriched for NK cells with an "adaptive", or human cytomegalovirus (CMV)-induced, phenotype.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-20
Trial Details
NCT Number NCT07591649
Lead Sponsor Masonic Cancer Center, University of Minnesota
Conditions Relapsed Adult AML, Refractory AML, Acute Myelogenous Leukemia
Enrollment 18 participants
Start Date 2026-05-08
Primary Completion 2030-03-01 (estimated)
Study Completion 2035-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-19